Respiratory Syncytial Virus Infections: all 302 studies

Page 2 of 4. Open to participants first (48), then studies with results posted, then the rest; newest registration first within each.

• Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSVCompletedNCT03636906Phase 1/2Results posted
• A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV SurveillanceCompletedNCT03614676Not applicableResults posted
• Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and ChildrenCompletedNCT03596801Phase 1Results posted
• Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and ChildrenCompletedNCT03387137Phase 1Results posted
• A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial VirusCompletedNCT03379675Phase 2Results posted
• An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old AdultsCompletedNCT03334695Phase 2Results posted
• A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus InfectionCompletedNCT03332459Phase 2Results posted
• Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of AgeCompletedNCT03227029Phase 1Results posted
• A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSVCompletedNCT03213405Phase 1Results posted
• Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of AgeCompletedNCT03102034Phase 1Results posted
• Nasal and Bronchial Absorption Sampling in RSV BronchiolitisCompletedNCT03062917Not applicableResults posted
• A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult WomenCompletedNCT02956837Phase 2Results posted
• A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive InfantsCompletedNCT02927873Phase 1/2Results posted
• Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of AgeTerminatedNCT02890381Phase 1Results posted
• A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.CompletedNCT02878330Phase 2Results posted
• RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old AdultsCompletedNCT02873286Phase 2Results posted
• Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of AgeCompletedNCT02794870Phase 1Results posted
• Cell Mediated Immunity Against RSV and Influenza in a Human Experimental ChallengeCompletedNCT02755948Not applicableResults posted
• Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy WomenCompletedNCT02753413Phase 2Results posted
• A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal ImmunizationCompletedNCT02624947Phase 3Results posted
• Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy WomenCompletedNCT02360475Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm InfantsCompletedNCT02325791Phase 3Results posted
• Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory TractCompletedNCT02254421Phase 2Results posted
• Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) InfectionCompletedNCT02135614Phase 2Results posted
• A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy AdultsCompletedNCT02114268Phase 1Results posted
• Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®CompletedNCT02016690Results posted
• Surveillance of Synagis in Korean Pediatric PatientsCompletedNCT01537198Results posted
• Respiratory Syncytial Virus - RSV ProtocolCompletedNCT01502072Phase 2Results posted
• Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)TerminatedNCT01475305Phase 1Results posted
• Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical ConditionsCompletedNCT01466062Phase 3Results posted
• The Development of a Human Model of Respiratory Syncytial Virus InfectionCompletedNCT01349543Not applicableResults posted
• Collection and Testing of Respiratory SamplesCompletedNCT01302418Results posted
• A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin AmericaCompletedNCT01297504Results posted
• Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in GermanyCompletedNCT01155193Results posted
• Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) InfectionCompletedNCT01107535Results posted
• Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart DiseaseCompletedNCT01075178Results posted
• Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian ChildrenCompletedNCT01006629Phase 2/3Results posted
• Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in ChildrenCompletedNCT00593918Results posted
• Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of AgeCompletedNCT00493285Phase 1Results posted
• Assessment of Airway Obstruction in Infants With Lower Respiratory InfectionsCompletedNCT00435994Not applicableResults posted
• Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) SeasonCompletedNCT00316264Phase 2Results posted
• Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV InfectionCompletedNCT00192504Phase 1Results posted
• Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk ChildrenCompletedNCT00129766Phase 3Results posted
• RSV, Influenza, and SARS-CoV-2 Outcomes in Severely Immunosuppressed AdultsActive, not recruitingNCT07816471
• Real-World Effectiveness of Nirsevimab Against RSV-Related and All-Cause Respiratory Tract Infections in Chinese InfantsCompletedNCT07382219
• Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in BogotáActive, not recruitingNCT07279298
• Diagnosis and Treatment Status and Medical Burden of Respiratory Syncytial Virus Infection in Children in ChinaActive, not recruitingNCT07264478
• A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus DiseaseActive, not recruitingNCT07220109Phase 3
• A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and OlderActive, not recruitingNCT07208461Phase 2
• A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney TransplantActive, not recruitingNCT07092865Phase 2
• Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of AgeCompletedNCT07071558Phase 1
• Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older AdultsActive, not recruitingNCT06984094Phase 1/2
• RSV Antibiotic Drivers And Resource-useCompletedNCT06977971
• A Study of AK0529 in Adults Patients Hospitalized With RSV InfectionCompletedNCT06942299Phase 2
• A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy ParticipantsCompletedNCT06917508Phase 1
• Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and OlderActive, not recruitingNCT06904222Phase 1
• Phase 2 Study of the RSV/Flu-01E Vaccine Against Respiratory Syncytial Virus Infection in Older AdultsCompletedNCT06890429Phase 2
• A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.CompletedNCT06847464Phase 1
• A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Time in Pediatric ParticipantsCompletedNCT06746051
• A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk InfantsCompletedNCT06710925Phase 3
• The Effect of Sevoflurane on Airway Hyperreactivity During the Perioperative Period.CompletedNCT06694675
• Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and OlderActive, not recruitingNCT06686654Phase 1/2
• Safety and Immunogenicity Study of SCB-1019T in ChildrenWithdrawnNCT06666179Phase 1
• A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and AboveActive, not recruitingNCT06645665Phase 1
• CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and SchoolsActive, not recruitingNCT06640387
• Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and OlderCompletedNCT06604767Phase 1
• A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy AdultsCompletedNCT06601192Phase 1
• RSV Vaccine in Transplant RecipientsActive, not recruitingNCT06593210Phase 3
• Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 YearsCompletedNCT06583031Phase 1
• A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 YearsCompletedNCT06573281Phase 1
• The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both ProductsCompletedNCT06551506Phase 4
• SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDERActive, not recruitingNCT06546800
• An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 StudyActive, not recruitingNCT06534892Phase 3
• A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy AdultsActive, not recruitingNCT06442241Phase 1
• Molecular and Microbiome/Metagenome Correlates of Recurrent Wheeze in RSV Infected InfantsCompletedNCT06424795
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for SuspensionCompletedNCT06328400Phase 1
• Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and OlderCompletedNCT06251024Phase 2
• Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and OlderCompletedNCT06237296Phase 1
• Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 YearsActive, not recruitingNCT06216093Phase 1
• A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSVCompletedNCT06206720Phase 2
• Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine CandidateCompletedNCT06134648Phase 1/2
• A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in InfantsCompletedNCT06083623Phase 2/3
• Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy AdultsCompletedNCT06033612Phase 1
• Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection KitCompletedNCT06008457
• Evaluation of RSV/Flu-01E Vaccine for the Prevention of RSV Infection in Volunteers Aged 18 to 59 Years and Over 60 YearsCompletedNCT05970744Phase 1
• Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and ToddlersCompletedNCT05964582
• A Study to Learn About Effect of Sisunatovir in Healthy Adult Male ParticipantsCompletedNCT05873764Phase 1
• Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational StudyCompletedNCT05794412
• A Study To Evaluate the Safety of XW001 Inhalation in Children With RSVCompletedNCT05779995Phase 1/2
• Combined Molecular Testing for Influenza, SARS-CoV-2, and RSV RNA From Different Upper Airway Specimens.Status unknownNCT05765838Not applicable
• SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (Level42)CompletedNCT05765396
• Project STARFISH - PRJ0002679CompletedNCT05727202
• Analysis of Lung Sounds Collected by RESP Biosensor to Support Decision Making in Monitored Hospitalized Pediatric PatientsWithdrawnNCT05661422
• A Study of XW001 in Healthy Adult SubjectsCompletedNCT05642403Phase 1
• A Study of TNM001 in Chinese Healthy Preterm and Term InfantsCompletedNCT05630573Phase 1/2
• A Study of EDP-323 in Healthy SubjectsCompletedNCT05587478Phase 1
• The Epidemiology , Health and Economic Burden of RSV Amongst Hospitalized Children Under 5 Years of Age in JordanStatus unknownNCT05562817
• Infant RSV Infections and Health-related Quality of Life of FamiliesStatus unknownNCT05550545
• A Dose Finding Study of VN-0200CompletedNCT05547087Phase 2
• Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older AdultsCompletedNCT05281263Phase 1

← Respiratory Syncytial Virus Infections overview